Advertisement () —

Emerging clinical evidence was highlighted at the Americas User Education Symposium hosted by TomoTherapy Incorporated ( (NASDAQ: TOMO) last month in Charleston, S.C. With more than 80 TomoTherapy customers in attendance, the meeting featured presentations from clinicians who submitted abstracts on how TomoTherapy@ radiation therapy technology is being effectively used for the treatment of numerous types of cancers. The meeting also explored TomoTherapy-related clinical and dosimetric trials, and how the system can be used to deliver stereotactic body radiation therapy (SBRT).

A key element of the TomoTherapy Americas User Education Symposium was a presentation by Minesh Mehta, M.D., professor of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago. The presentation provided an overview of TomoTherapy treatment-related studies that included tumors of the brain, head and neck, breast, lung, pelvis, as well as treatment of multiple body metastases.

An important aspect of the presentation was increasing evidence that TomoTherapy technology is well-suited for image-guided SBRT, which could serve as an effective treatment option for patients with early-stage lung cancer who are considered inoperable because of complications, such as poor cardiopulmonary function. "TomoTherapy is ideally-suited for an image-guided stereotactic radiotherapy approach. It enables us to target the early-stage cancerous lesions of the lung without damaging healthy lung tissue, and allows us both excellent outcomes and good control rates," concluded Dr. Mehta.

Benjamin Sintay, Ph.D., lead clinical physicist, Moses Cone Regional Cancer Center, Greensboro, N.C., also addressed the topic of SBRT, reporting on his center's successful use of the TomoTherapy system to deliver SBRT for 18 percent of their patients, including those presenting with lung, liver, paraspinal and bone cancers. In another study, Paul Read, M.D., Ph.D., University of Virginia, Charlottesville, Va., presented his center's use of the TomoTherapy system to deliver highly-precise, SBRT-like dose distributions for hypofractionated palliative care of patients, which resulted in "more rapid and patient-convenient palliation with less toxicity."

"The program at our Americas User Education Symposium clearly illustrates the broad clinical application of our technology," said Stephanie Key, TomoTherapy's director of clinical marketing. "It is great to be able to provide a forum for sharing experiences in the use of the TomoTherapy system."

About TomoTherapy Incorporated TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy@ platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its Hi-Art@ treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

5/82011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, TomoMobile, TomoDirect, TQA, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.